You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

77 search results for: disease control

interactivity

Pediatric Asthma Patient Case Tool: Ash

5 min

Pulmonology

Review a patient case to learn more about identifying uncontrolled asthma and type 2 inflammation in pediatric patients

interactivity

On-Treatment Clinical Remission in Asthma Patients Case Tool

7 min

Pulmonology

Review a severe asthma patient case to learn more about assessing asthma control and on-treatment clinical remission.

expert video

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

7 min

Rhinology

Prof. Joaquim Mullol describes the burdens of smell loss and nasal congestion for patients with uncontrolled and/or severe CRSwNP.

Targeting Underlying Inflammation in CRSwNP, a Type 2 Inflammatory <b>Disease</b>

expert video

Targeting Underlying Inflammation in CRSwNP, a Type 2 Inflammatory Disease

10 min

Rhinology

Professor Martin Wagenmann describes the mechanisms through which type 2 inflammation drives symptoms in patients with CRSwNP.

expert video

EAACI 2024 Emerging Definitions of Clinical Remission and Achieving Clinical Remission With Biologics for Patients With Asthma

13 min

Pulmonology

Join Professor Vibeke Backer for a presentation on clinical remission in asthma and achieving remission with biologics for patients with uncontrolled asthma.

interactivity

Type 2 Inflammation Digital Assessment Tool

4 min

Pulmonology

Learn how to assess patients for the presence of uncontrolled asthma driven by underlying type 2 inflammation.

expert video

Biologics in CRSwNP: Comparative Efficacy and Real-World Effectiveness

10 min

Rhinology

Professor Eugenio De Corso discusses indirect comparisons of biologics approved for patients with uncontrolled CRSwNP and emerging real-world effectiveness of biologics for patients with CRSwNP.

Why targeting Type 2 Inflammation is important in the treatment of skin <b>disease</b>s like AD, PN and CSU

expert video

Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU

5 min

Dermatology

Dr. Palomares discusses how type 2 inflammation, an aberrant immune response, underlies skin diseases like atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, linking to their clinical symptoms.

CRSwNP: A Chronic Type 2 Inflammatory <b>Disease</b>

expert video

CRSwNP: A Chronic Type 2 Inflammatory Disease

2 min

Rhinology

Prof. Peter Hellings describes how type 2 inflammation drives CRSwNP.

Why did the definition of <b>control</b> in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

expert video

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

5 min

Rhinology

Prof. Hellings and Prof. Corso discuss the significance and rationale behind the new definition of CRSwNP.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: SwedenChange country/region